A comprehensive review about the utilization of immune checkpoint inhibitors and combination therapy in hepatocellular carcinoma: an updated review

A comprehensive review about the utilization of immune checkpoint inhibitors and combination therapy in hepatocellular carcinoma: an updated review

Abstract A pharmacological class known as immune checkpoint inhibitors (ICIs) has been developed as a potential treatment option for various malignancies, including HCC. In HCC, ICIs have demonstrated clinically significant advantages as monotherapy or combination therapy. ICIs that target programme...

Full description

Bibliographic Details
Main Authors: Faezeh Sharafi, Sadegh Abaei Hasani, Samira Alesaeidi, Mohammad Saeed Kahrizi, Ali Adili, Shadi Ghoreishizadeh, Navid Shomali, Rozita Tamjidifar, Ramin Aslaminabad, Morteza Akbari
Format: Article
Language:English
Published: BMC 2022-08-01
Series:Cancer Cell International
Subjects:
Immune checkpoint inhibitors
Hepatocellular carcinoma
Combination therapy
Online Access:https://doi.org/10.1186/s12935-022-02682-z

Internet

https://doi.org/10.1186/s12935-022-02682-z

Similar Items